Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Hayes

Showing results (111-120 of 130) with videos related to

Pageof 13
Sort By:
Plos One|August 8, 2015
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African AdultsJuliet Mpendo, Gaudensia Mutua, Julien Nyombayire, et al.
AIDS Research and Human Retroviruses|July 30, 2010
A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virusEftyhia Vardas, Pontiano Kaleebu, Linda-Gail Bekker, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 30, 2013
Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1Nicola Borthwick, Tina Ahmed, Beatrice Ondondo, et al.
Rural and Remote Health|January 11, 2023
The Limerick Declaration on Rural Health Care 2022Liam Glynn, Andrew W Murphy, Robert Scully, et al.
BJGP Open|May 19, 2021
SARS-CoV-2 infection in general practice in Ireland: a seroprevalence studyMichael E O'Callaghan, Elizabeth Ryan, Cathal Walsh, et al.
Journal of Virology|April 28, 2006
Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopesNilu Goonetilleke, Stephen Moore, Len Dally, et al.
AIDS Research and Human Retroviruses|December 1, 2009
A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteersVadakkuppatu Devasenapathi Ramanathan, Makesh Kumar, Jayashri Mahalingam, et al.
Plos One|May 12, 2015
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African AdultsGloria Omosa-Manyonyi, Juliet Mpendo, Eugene Ruzagira, et al.
Molecular Therapy. Methods & Clinical Development|September 13, 2016
Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adultsGaudensia Mutua, Bashir Farah, Robert Langat, et al.
Vaccine|June 6, 2020
Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in GuineaYap Boum, Aitana Juan-Giner, Matt Hitchings, et al.
Pageof 13

Showing results (111-120 of 130) with videos related to

Sort By:
Pageof 13
Plos One|August 8, 2015
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African AdultsJuliet Mpendo, Gaudensia Mutua, Julien Nyombayire, et al.
AIDS Research and Human Retroviruses|July 30, 2010
A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virusEftyhia Vardas, Pontiano Kaleebu, Linda-Gail Bekker, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 30, 2013
Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1Nicola Borthwick, Tina Ahmed, Beatrice Ondondo, et al.
Rural and Remote Health|January 11, 2023
The Limerick Declaration on Rural Health Care 2022Liam Glynn, Andrew W Murphy, Robert Scully, et al.
BJGP Open|May 19, 2021
SARS-CoV-2 infection in general practice in Ireland: a seroprevalence studyMichael E O'Callaghan, Elizabeth Ryan, Cathal Walsh, et al.
Journal of Virology|April 28, 2006
Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopesNilu Goonetilleke, Stephen Moore, Len Dally, et al.
AIDS Research and Human Retroviruses|December 1, 2009
A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteersVadakkuppatu Devasenapathi Ramanathan, Makesh Kumar, Jayashri Mahalingam, et al.
Plos One|May 12, 2015
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African AdultsGloria Omosa-Manyonyi, Juliet Mpendo, Eugene Ruzagira, et al.
Molecular Therapy. Methods & Clinical Development|September 13, 2016
Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adultsGaudensia Mutua, Bashir Farah, Robert Langat, et al.
Vaccine|June 6, 2020
Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in GuineaYap Boum, Aitana Juan-Giner, Matt Hitchings, et al.
Pageof 13